Company ProfilePremium

Good Fellow Healthcare Holdings Limited

Company Profile Analysis

金威醫療集團有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Good Fellow Healthcare Holdings Limited - Company showcase

Year Founded & Workforce

2001

137 Employees

Good Fellow Healthcare Holdings Limited logo

Good Fellow Healthcare Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Good Fellow Healthcare Holdings Limited Overview

Good Fellow Healthcare is a micro-cap, Hong Kong-headquartered holding company listed on GEM. It is in the middle of a forced transition from owner-operator of PRC general hospitals to an asset-light healthcare-services and hospital-management platform.

Its only physical hospital, in Beijing (now named Beijing Huicheng Hospital, formerly Beijing Zijing), has been suspended since 12 December 2024 and produced no revenue in FY2026. Revenue of HK$20.06m in FY2026 came almost entirely from a five-year operating-management agreement with the Yueerwan (Qingdao) Internet Hospital. That agreement carries a contractual minimum fee of HK$1.75m per month.

Management's stated ambition is an "integrated healthcare-services platform" anchored on specialty hospitals. Current projects include:

  • a licensed but unbuilt Grade III specialty hospital in Hainan's Boao Lecheng Pilot Zone;

  • a proposed RMB5.74m purchase of a look-through 40.8% interest in a 30-year-old Xiamen secondary hospital.

The group is founder-controlled, has very low liquidity and depends on frequent equity issuance.


Company's own description

In its FY2026 annual report, the Company describes itself as an investment holding company whose subsidiaries are principally engaged in providing general hospital services in the PRC [AR26, Report of the Directors].

The FY2026 outlook restates the group objective. The aim is an integrated healthcare-services platform in the PRC, anchored on specialty hospital services and complemented by hospital management and digital-healthcare cooperation [AR26, MD&A].

Market data vendors describe the historic service scope as medical and surgical wards, cosmetic surgery, dermatology, and medical check-up and examination services [AGG, Morningstar]. A company profile on moomoo describes a "Jinwei Medical Model" of medical investment, M&A, management consulting, special planning, training and entrusted hospital management [AGG, moomoo company page].

Independent characterisation

In economic substance, Good Fellow is no longer a hospital operator in FY2026. It is a management-services contractor with an option on future hospital assets.

Revenue model.

FY2024: 100% point-in-time patient revenue from hospital services, totalling HK$38.962m [AR25-RA, Note 5].

FY2025: HK$10.945m point-in-time hospital revenue plus HK$5.175m recognised over time. The over-time amount is consistent with management-service fees under the October 2024 Yueerwan agreement [AR25-RA, Note 5; AR26 revenue recognition policy].

FY2026: No hospital segment revenue [AR26, Chairman's Statement]. Effectively all HK$20.060m was hospital-management services revenue, recognised straight-line (derived).

Revenue mix by type (FY2026, derived). Services 100%, products 0%, subscription/licensing 0%. The management fee is contractually a minimum fixed monthly fee, so it behaves like a recurring service retainer.

Value-chain position. The group sits at the provider/operator layer of PRC healthcare delivery:

  • historically as a private hospital owner (Putian, Jiaxing, Beijing);

  • currently as an outsourced operating partner to an internet hospital licensed to a third party (Yueerwan Qingdao).

Customer types.

  • Historically: retail patients, self-pay and insured.

  • Currently: a single B2B counterparty (Yueerwan Qingdao/Xiamen Yueerwan).

The FY2026 annual report states that no individual customer contributed over 5% of revenue [AR26]. That is difficult to reconcile with a single management contract that delivered principal revenue. The likely explanation is that "customers" is defined at the patient level, or that the statement carried over boilerplate. This is a disclosure inconsistency investors should query.

End-markets.

  • Mainland China private hospital services.

  • Internet hospital and telemedicine operations.

  • Prospective medical tourism and specialty care in the Hainan Free Trade Port (Boao Lecheng).

Strategy

Stated strategy (themes from AR26)

Integrated platform. The objective is an integrated healthcare-services platform in the PRC, anchored on specialty hospital services and complemented by hospital management and digital-healthcare cooperation.

Follow regional demand. Management observes that demand for high-quality specialty services is concentrating in regions with more favourable policy environments and mature healthcare ecosystems. The cited service areas are cardiovascular health, sports medicine, preventive care and healthy ageing. This is the rationale for Hainan.

Buy licensed assets. The group will pursue hospital-related acquisitions, specifically interests in hospitals that already hold licences and have an established patient base. The Xiamen deal is the first instance.

Recurring fee base. Hospital management and digital health are positioned as providing a recurring, more balanced revenue base.

Execution philosophy. An action plan built on technology-driven efficiency, optimised resource deployment and innovation, carried out with "prudent optimism".

Initiatives in the last 24 months

InitiativeDateDescriptionStatusSource
Yueerwan internet hospital managementOct 2024Five-year management contract with acquisition optionGenerating all revenueAR25-RA
Beijing hospital relocation/resumptionFY2025 to FY2026Site identified, then reassessed; considering a representative office or health centreUnder reviewAR25-RA; AR26
Rights issueMar–Jun 2025HK$26.79m net; HK$10.6m to shareholder loans, HK$8.3m to hospital business, HK$7.8m to working capitalFully utilisedAR26
2025 Share Option SchemeMay 2025Scheme mandate of 56,364,998 shares; no grants to dateAdoptedAR26
Hainan Grade III specialty hospitalDec 2025Establishment and site approvals; premises leasedLicence application not yet filedAR26
Hainan healthcare technology exhibition hallH1 2026AI, wearables, telemedicine showcase and test bedOperatingAR26
April 2026 share subscriptionApr 2026HK$19.09m net, mainly for healthcare investment; HK$6m for working capital to Jan 2027CompletedPUBT
Capital reorganisationApr–Sep 20265-into-1 consolidation; par cut to HK$0.01; creates approx. HK$55.56m distributable reserveEffective 22 Sep 2026AR26; HKEX-MKT
Xiamen hospital acquisitionJun 202680% of Chengkan partnership (holds 51% of Xiamen Huli Jianmin Hospital) for RMB5.74mPendingPUBT

Guidance and targets

No quantitative revenue, margin or profitability guidance has been issued. No medium-term financial targets, ESG targets or cost-reduction targets are disclosed.

Products & Services

Hospital management and operational partnership services (current revenue engine)

Yueerwan (Qingdao) Internet Hospital operating partnership. Good Fellow Development provides hospital management services to Yueerwan (Qingdao) Internet Hospital Co., Ltd. and the Qingdao Yueerwan Internet Hospital [AR25-RA].

Fee terms: The higher of:

  • (i) a fixed monthly fee of HK$1.75m; or

  • (ii) 1% of the internet hospital's audited operating revenue plus 10% of its audited profit before tax.

Term: Five years from 25 October 2024. Neither party can terminate without cause in year one. From years two to five, either party may terminate on three months' notice.

Option: Xiamen Yueerwan granted the group an option to acquire all or part of the shares of Yueerwan Qingdao and the Internet Hospital during the term, on terms to be negotiated.

Target customer: The single contractual counterparty.

Launch year: FY2025 (October 2024).

Pricing model: A minimum retainer with a performance kicker.

Economics (derived): The minimum fee implies HK$21.0m per year. FY2026 revenue of HK$20.06m is consistent with the fee being billed at or near the floor, net of any adjustments. The contract therefore accounts for essentially all current revenue.

Termination risk: Because the year-one lock-up expired on 25 October 2025, the counterparty can now exit on three months' notice. This is the single largest risk to the revenue base.

General hospital services (suspended)

Beijing Huicheng Hospital (formerly Beijing Zijing Hospital), Dongcheng District, Beijing.

Services: Medical wards, surgical wards, medical check-up and examination [AR25-RA].

Status: Suspended since 12 December 2024, with no revenue in FY2026 [AR26].

Earlier suspension: A previous suspension ran from 29 December 2023 to around March 2024 after 13 demerit points accumulated in 2023 [HKEX-ANN 3 Jan 2024, 31 Jan 2024; FY24-RA].

Relocation plans: FY2025 management said a new site had been identified in Beijing, with department planning and recruitment under way [AR25-RA].

Latest position: By FY2026 management had reframed this. Given business contraction and structural change in the general-hospital market, it is reassessing whether to reopen at all. Options under consideration include a representative office and a customer-reception health centre [AR26].

Pricing: Not publicly disclosed.

Hainan Grade III specialty hospital (pre-operational)

Approvals: Hainan Good Years Medical Services received a medical institution establishment approval dated 10 December 2025 and a site approval from the Medical Products Administration of the Boao Lecheng International Medical Tourism Pilot Zone [AR26].

Specialty: The interim report summary describes the hospital as a cardiovascular specialty hospital [etnet summary of the 2025/26 Interim Report]. The FY2026 annual report emphasises demand for cardiovascular health, sports medicine, preventive care and healthy ageing [AR26].

Premises: Lease agreements were signed for hospital premises and medical facility space in the Pilot Zone during H1 FY2026, and a dedicated hospital chief executive was appointed [IR26 via Bulletin Express].

Status at report date: Renovation, equipment procurement, hospital IT systems and medical staff recruitment were not complete. The Medical Institution Practising Licence application had not been filed [AR26].

Delays: The employee leading the licence application left the group, and the regulatory approval process and competent authority have changed [AR26].

Timetable: No definitive timetable [AR26].

Bed count, capex budget, pricing: Not publicly disclosed.

Healthcare technology exhibition hall (Boao Lecheng)

During H1 2026 the group established and operated a healthcare technology exhibition hall in the Pilot Zone. It showcases AI, wearable devices, remote consultation and internet-hospital operations [AR26].

Management frames the hall as a market-validation test bed. It says the assets (internet hospital platform, remote consultation facilities, medical AI applications, technical team) can be reused across future projects. The group also exhibited at the 6th China International Consumer Products Expo (Lecheng session) [AR26]. Revenue contribution is not disclosed and is believed to be nil or immaterial.

Historic and discontinued offerings (for completeness)

OfferingDescriptionStatusSource
Edinburgh International Hospital, Putian (Fujian)200-bed general hospital focused on paediatrics and diabetes, JV with University of EdinburghLicensed Jul 2020; Putian hospital no longer reported by FY2024 (group operated one Beijing hospital only). Exit route not confirmed in materials reviewed.Univ. of Edinburgh; HKEX-ANN 2020; AR25-RA
Jiaxing plastic-surgery hospitalCosmetic surgery hospitalSold Mar 2020 for HK$11mAAStocks/uSMART
Chongqing hospital consultancyConsultancy agreement with a Chongqing hospital (2 Jan–1 Mar 2024) to offset the Zijing suspensionCompletedHKEX-ANN 31 Jan 2024
Cosmetic surgery and dermatologyHistoric service lines cited by vendorsNot currentAGG (Morningstar)

Financial Narrative

Income statement

Sources.

  • FY2024–FY2025: AR25-RA (audited).

  • FY2026: AR26 and FY26-RA. FY2026 cost of sales is derived as revenue less gross profit.

  • FY2022–FY2023 revenue: TipRanks/stoxray [AGG]. The FY2023 loss is corroborated by the FY2024 profit warning, which cites HK$5.88m [FY24-RA].

  • FY2022 loss: stoxray [AGG], consistent with the HK$10.6m decline in owners' equity between 1 April 2021 and 1 April 2022 [HKEX-ANN interim FY2023].

Sources: AR25-RA and FY26-RA. No dividends have been declared for FY2024–FY2026. These figures are pre-September 2026 consolidation. Adjusted for the 5-into-1 consolidation, FY2026 loss per share would be approximately -6.2 cents (derived).

All derived. FY2022 growth is calculated against FY2021 revenue of HK$53.886m [AGG]. The revenue CAGR from FY2022 to FY2026 is -22.0% per year (derived).

Reconciliation and disclosure issues.

  1. The FY2026 MD&A states revenue growth of "approximately 22.44%", while the Chairman's Statement says 24.44%. Arithmetic (20.060/16.120) supports 24.44% [AR26].

  2. The MD&A describes FY2026 gross profit of HK$10.602m as a "decrease of 26.68%". It was in fact an increase of 26.7% from HK$8.369m [AR26].

  3. The FY2026 operating loss does not reconcile with the itemised lines disclosed in MD&A. Gross profit 10.602, plus other revenue 0.010, plus other gains 0.626, less S&D 2.290, less admin 14.681, gives -5.733, against the reported -12.373. That leaves approximately HK$6.64m of other charges (derived) not itemised in the sections reviewed. Likely candidates are impairment or expected credit loss items. Investors should check the full income statement on AR26 p.72.

Interim profile (H1 FY2026, six months to 30 Sep 2025) [IR26].

  • Revenue HK$10.500m (H1 FY2025: HK$10.435m).

  • Gross margin 79.37% (78.40%).

  • Loss attributable HK$2.671m, against a profit of HK$7.602m that had been flattered by the HK$10.458m disposal gain.

By subtraction, H2 FY2026 revenue was approximately HK$9.56m. Gross profit was only about HK$2.27m, a gross margin of roughly 24% (derived). This points to a sharp second-half cost step-up, possibly Hainan preparatory staff and exhibition-hall costs charged to cost of sales. It warrants scrutiny.

Commentary on income statement trends

The five-year arc falls into three phases.

FY2021–FY2023: stable decline. Revenue was broadly flat at HK$54–55m, generated by the hospital portfolio after disposals. Losses narrowed from HK$12.7m to HK$5.9m. The improvement was helped in FY2022 by a HK$31.7m one-off disposal gain within the nine-month period [HKEX-ANN 2 Feb 2023].

FY2024: regulatory shock. Revenue fell 29.6% to HK$38.96m. The Beijing hospital was suspended for roughly two months after accumulating 13 regulatory demerit points. The group also took HK$3.5m of non-financial asset impairment and a HK$2.1m loss on PPE disposal [AR25-RA comparatives; FY24-RA]. The attributable loss widened 191% to HK$17.1m.

FY2025–FY2026: collapse of the hospital model and pivot to management fees.

  • The Beijing hospital was suspended again from 12 December 2024 and remained closed through FY2026.

  • Revenue bottomed at HK$16.1m in FY2025, then recovered to HK$20.1m on a full year of Yueerwan fees.

  • FY2025's reported loss was flattered by a HK$10.5m disposal gain. It was simultaneously burdened by a HK$7.8m loss on disposing of hospital PPE.

  • In FY2026 there were no one-offs. The underlying cost base of about HK$17m in S&D plus admin, plus unexplained charges, exceeded gross profit, and the attributable loss widened to HK$12.5m.

Staff costs fell from HK$22.7m (FY2024) to HK$13.1m (FY2025) and HK$9.0m (FY2026) [AR25-RA; AR26]. Headcount fell from 137 to 21, then rose to 28.

Balance sheet

Sources. FY2024–FY2025 from AR25-RA (statement of financial position). FY2026 cash, current assets and current liabilities from AR26 MD&A. Totals, net debt and working capital are derived.

FY2026 gaps.

  • The FY2026 gearing ratio of 5.75% (debt from a director and other loans, divided by total equity) confirms that the group returned to positive equity with minimal debt [AR26].

  • Goodwill and intangibles are shown as zero because no such line appears on the FY2024–FY2025 balance sheets.

Capital-structure disclosure error. AR26 states that issued share capital at 31 March 2026 was HK$57.350m. It then describes this as 563,649,988 ordinary shares, which is the pre-rights-issue count. The correct count is 1,127,299,976 shares at HK$0.05, equal to HK$56.365m, plus 19.7m preference shares at HK$0.05, equal to HK$0.985m, totalling HK$57.350m (derived).

Cash flow

Dividends paid and buybacks were nil throughout FY2024–FY2026 [AR25-RA; AR26].

The main financing inflows in FY2026 were:

  • rights issue net proceeds of HK$26.794m (June 2025), of which HK$10.6m repaid shareholder loans [AR26]; and

  • after the year end, subscription proceeds of HK$19.09m (April 2026).

Ratios

Notes.

  • Current ratios and gearing are as reported [AR25-RA; AR26]. The FY2024 gearing ratio was reported as "N/A" and is entered as 0 to keep the column numeric.

  • Other ratios are derived.

  • ROE, ROIC, net debt/EBITDA and interest coverage are not meaningful. Equity was negative or near zero, EBITDA was negative, and the group was loss-making at operating level in every year shown.

  • The cash conversion cycle cannot be computed (no inventory or trade payables in FY2025–FY2026).

  • Interim note: current ratio at 30 September 2025 was 9.26x, with current liabilities of only HK$1.868m [IR26]. Current liabilities then rose to HK$17.549m by March 2026. The composition of that increase is not disclosed in the excerpts reviewed and warrants checking against AR26 Notes.

Going concern and liquidity

At 31 March 2025 the group had net liabilities of HK$6.755m. The directors relied on the June 2025 rights issue to support the going-concern basis [AR25-RA, Note 2].

By 31 March 2026 the board stated that:

  • the rights issue, shareholder loan repayment, and disposal of non-core loss-making operations had restored the group to net assets; and

  • the April 2026 subscription further strengthened liquidity [AR26].

The capital reduction is intended to create a distributable reserve of approximately HK$55.56m. This is a technical step enabling future distributions or corporate actions, not new capital [AR26].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Segment / Stream (HKD Mn)FY2024FY2025FY2026

General hospital services (point-in-time)

38.96210.9450

Hospital management services (over time)

05.17520.060

Total revenue

38.96216.12020.060

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment share of revenue (%)

Segment share of revenue (%)FY2024FY2025FY2026

General hospital services

100.067.90.0

Hospital management services

0.032.1100.0

Segment YoY growth (%)

Segment YoY growth (%)FY2024FY2025FY2026

General hospital services

-29.6-71.9-100.0

Hospital management services

00287.6

Total

-29.6-58.624.4

Group Entities

EntityRoleStatusSource

Good Fellow Healthcare Holdings Limited

Listed holding company (Cayman)

Active

AR26

Solar Star Global Limited

Immediate holding company (not a subsidiary)

Owned by the Ng family

AR25-RA

Beijing Huicheng Hospital Co., Ltd. (formerly Beijing Zijing Hospital Co., Limited)

Indirect non-wholly-owned subsidiary; general hospital in Dongcheng District, Beijing

Suspended since 12 Dec 2024

AR25-RA; HKEX-ANN 3 Jan 2024

Good Fellow Development Limited

Indirect wholly-owned subsidiary; counterparty to the Yueerwan management agreement

Active

AR25-RA

Hainan Good Years Medical Services Co., Ltd.

Indirect wholly-owned subsidiary; Hainan hospital project

Pre-operational

AR26

Good Fellow Innovation Co., Ltd.

Indirect wholly-owned subsidiary; tenant of HK office lease (Mar 2024)

Active (per 2024 disclosure)

Zhitong via moomoo

Sino Business Investment Development Limited

Former direct wholly-owned subsidiary

Disposed 23 Sep 2024

AR25-RA

Income Statement

Metric (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Revenue

54.23855.35338.96216.12020.060

Cost of sales

——20.2887.7519.458

Gross profit

——18.6748.36910.602

Selling and distribution expenses

——8.9183.1052.290

Administrative expenses

——20.27115.06014.681

Operating loss (reported as loss from operations)

——-16.036-7.178-12.373

Finance costs

——0.3080.1900.152

Loss before tax

——-16.344-7.368-12.525

Loss for the year (total)

——-17.387-7.357—

Loss attributable to owners

-12.689-5.881-17.110-10.127-12.523

Per-share metric (HK cents)

Per-share metric (HK cents)FY2024FY2025FY2026

Basic and diluted loss per share

-3.04-1.80-1.24

Dividend per share

000

Margin / growth metric (%)

Margin / growth metric (%)FY2022FY2023FY2024FY2025FY2026

Revenue growth YoY

0.72.1-29.6-58.624.4

Gross margin

——47.951.952.9

Operating margin

——-41.2-44.5-61.7

Net margin (attributable)

-23.4-10.6-43.9-62.8-62.4

Balance Sheet

Metric (HKD Mn, at 31 March)FY2024FY2025FY2026

Property, plant and equipment

16.0351.273—

Right-of-use assets

4.1380—

Total non-current assets

20.4411.273—

Inventories

1.0630—

Trade and other receivables

3.7614.414—

Cash and bank balances

3.6443.82913.391

Total current assets

8.7058.55924.209

Total assets

29.1469.832—

Borrowings (current)

7.09910.529—

Lease liabilities (current + non-current)

5.1300—

Total current liabilities

25.61516.58717.549

Total liabilities

27.73916.587—

Net debt (borrowings + leases − cash)

8.5856.700—

Working capital (net current assets)

-16.910-8.0286.660

Equity attributable to owners

4.357-6.509—

Non-controlling interests

-2.950-0.246—

Total equity

1.407-6.755—

Goodwill and intangibles

00—

Cash Flow

Metric (HKD Mn)FY2021FY2022FY2023FY2024

Operating cash flow

1.248-22.925-1.320-0.854

Financial Ratios (x) and Margin Analysis (%)

RatioFY2024FY2025FY2026

Current ratio (x)

0.340.521.38

Gearing ratio as reported (%)

099.195.75

ROA (loss for year / average total assets, %)

—-37.7—

Asset turnover (revenue / average total assets, x)

—0.83—

Revenue per employee (HKD Mn)

0.280.770.72

Staff costs / revenue (%)

58.281.145.0

Region revenue (HKD Mn)

Region revenue (HKD Mn)FY2024FY2025FY2026

Mainland China (PRC)

38.96216.12020.060

Hong Kong

000

Rest of world

000

Region growth YoY (%)

Region growth YoY (%)FY2024FY2025FY2026

Mainland China (PRC)

-29.6-58.624.4

Share price (HK$, pre-consolidation)

Share price (HK$, pre-consolidation)Apr 2025Mar 2025Feb 2026Apr 2026Jun 2026

Observed price

0.0890.0570.1030.0860.077

Capital Markets

ItemStatus

Sell-side analyst consensus

None identified

Dividend history

No dividends for FY2024–FY2026; no distributable reserves at 31 Mar 2026 (AR26)

Dividend policy

Not formally disclosed; the capital reduction creates an approx. HK$55.56m distributable reserve

Buyback authorisation

Repurchase mandate of up to 10% of issued shares sought at the 9 Sep 2026 AGM; no repurchases in FY2025

Credit ratings (Moody's / S&P / Fitch)

Not rated

Bank borrowings

None at 31 Mar 2025 or 2026; no asset charges (AR25-RA; AR26)

Debt maturity profile

Not applicable beyond small director and other loans (gearing 5.75%)

Share capital metric (millions of shares)

Share capital metric (millions of shares)Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026

Ordinary shares in issue

2,818.25563.65563.651,127.30270.55

Analyst Conclusions

Management guidance

There is no numerical guidance. Management's qualitative priorities are:

  • advance the Hainan Grade III hospital, without a timetable;

  • complete the Xiamen hospital acquisition;

  • keep evaluating licensed-hospital acquisitions;

  • sustain the Yueerwan management relationship;

  • decide the configuration of the Beijing business (representative office or health centre) [AR26].

Consensus expectations. None, as there is no coverage.

Bull case

  1. Floor revenue plus optionality. The HK$21m-per-year Yueerwan minimum fee covers most of the cash cost base (S&D plus admin of about HK$17m in FY2026). The acquisition option and Xiamen deal could convert the group into an owner of licensed assets cheaply, at RMB5.74m for a look-through 40.8% hospital interest.

  2. Clean balance sheet for a pivot. Cash of HK$13.4m at March 2026 plus HK$19.1m raised in April 2026, together with near-zero debt, gives roughly HK$30m+ of dry powder (derived, before FY2027 burn) for small acquisitions.

  3. Hainan scarcity value. Valid Grade III specialty-hospital approvals in Boao Lecheng have value in themselves, and could be monetised or partnered even if the group does not build out alone.

Bear case

  1. One contract away from zero revenue. The counterparty may terminate on three months' notice. Loss of the contract would leave the group with no revenue-generating operations.

  2. Losses and dilution are structural. The attributable loss widened to HK$12.5m despite 24% revenue growth. There is about HK$6.6m of unexplained charges and an H2 gross margin of about 24%. Shares in issue rose 2.4x in ten months.

  3. Execution and governance credibility. The record includes:

    • repeated Beijing suspensions;

    • Hainan licensing slippage;

    • a reorganisation delayed by an incomplete Cayman filing;

    • multiple errors in the annual report;

    • a 26.6% share security interest;

    • an acquisition target with a large net loss and questionable reported net liabilities.

Catalysts and monitorables (next 12 months)

  1. Completion, final terms and financing of the Xiamen Huli Jianmin acquisition, and restated target financials (net liabilities).

  2. Any notice or renegotiation under the Yueerwan agreement, or exercise of the acquisition option.

  3. Filing and grant of the Hainan Medical Institution Practising Licence; construction and capex disclosures.

  4. Decision on the Beijing Huicheng business (closure, write-off or health-centre format).

  5. Interim results for H1 FY2027 (six months to 30 Sep 2026), due around November 2026: cash burn, the H2-style margin compression, and the use of April proceeds.

  6. Further equity issuance under the AGM mandate and any changes to the Dejin Liangpin security interest or the controlling stake.

  7. Post-consolidation trading liquidity and GEM compliance.

Analyst verdict

Good Fellow Healthcare is best understood today as a listed shell in transition, not an operating hospital group. Its revenue line, HK$20.06m in FY2026, is one management contract with a contractual floor. That contract became cancellable on short notice in October 2025.

The group's only hospital has been dark for nearly two years. The flagship Hainan project has approvals but no licence application, no budget and no timetable. Senior capability is thin: 28 staff, no CEO, and no medical leader on the board.

Against that, the board has done the necessary balance-sheet triage:

  • negative equity was repaired;

  • shareholder loans were repaid;

  • bank debt was eliminated;

  • roughly HK$46m of net equity capital was raised across two transactions;

  • the capital structure was simplified to meet GEM trading norms.

The new strategy of buying already-licensed hospitals cheaply is coherent in a PRC market where private hospital numbers are now shrinking and distressed assets are available. The question is whether this team can operate them better than the previous owners, given its own regulatory track record in Beijing.

Disclosure quality is a material concern. The FY2026 annual report contains arithmetic and narrative errors. Operating charges of about HK$6.6m are not itemised in the sections reviewed. The first acquisition target's reported net liabilities, at around RMB772m, are implausible on their face. A security interest over more than a quarter of the shares adds control uncertainty.

For institutional purposes, the equity is uninvestable on fundamentals. It has no coverage, minimal liquidity, persistent losses and serial dilution. It is relevant only as a special situation contingent on:

  • completion and transparent consolidation of the Xiamen hospital;

  • retention of the Yueerwan contract; and

  • tangible Hainan licensing progress.

Verdict: High risk / Speculative. Monitor for evidence of operating-asset accretion before assigning value beyond net cash.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleAppointedAgeEducation / prior rolesSource

Ng Chi Lung

Chairman, Executive Director, Compliance Officer, Chair of Nomination and CG Committee; controlling shareholder

23 Jul 2018

37

Diploma, Sydney Institute of Business and Technology (2008); studied accounting at Macquarie University. Founder of manufacturing and services businesses since 2012. ED of Yueshou Environmental (now China Gem Holdings, 1191.HK) 2014–2016; Vice Chairman and ED of Theme International (990.HK) 2016–2018

AR26

Wu Qiyou

Executive Director; Remuneration Committee member

22 Aug 2023

32

B.Bus (Banking and Finance, 2016) and MBA (2022), Monash University. Investment manager, Cornerstone Capital Investment Group (2016–2020); management team, Lunghealth Medtech (2021–2022, magnetic navigation bronchoscopy); founder and CEO, Dynamiq Advisory Pte Ltd (since Dec 2022)

AR26

Wong Ka Wai, Jeanne

INED; Chair of Audit and Remuneration Committees

1 Nov 2007

62

B.Econ, University of Sydney; CA ANZ, HKICPA, STEP, Certified Tax Adviser. MD of a consulting firm, CFO of a local law firm. INED of Phoenitron Holdings (8066.HK)

AR26

Lau Tak Kei Arthur

INED

4 Oct 2019

44

LLB (LSE); M.Econ (HKU); SFC Type 4/9 licensed. Co-founder and partner of Ark Pacific Capital Management. Former investment director, Elliott Advisors (HK); Citigroup TMT investment banking; started at JPMorgan. Member of the Beijing Municipal Committee of the CPPCC

AR26

Lin Yaomin

INED

17 Apr 2024

65

B.Sc Nanjing University (1982); M.Sc Chinese Academy of Sciences; senior economist; FLMI (1999). GM of Ping An Life Xiamen (1995–2000) and Hubei (2000–2002); Kunlun Health Insurance (2006–2015), latterly Chairman and CEO; senior consultant, Airstar Digital Technology (2017–2021); founder of Insurance Today research institute

AR26

Lam Williamson

CFO and Company Secretary; Authorised Representative

Joined Dec 2007

51

CPA Australia; FCPA (HKICPA)

AR26

Directors' Remuneration

AttributeDetail

Board size

5 (2 executive, 3 INEDs)

Independence

60% INEDs

Chair/CEO separation

No CEO; Chairman is the controlling shareholder

Gender

1 female of 5 directors (20%)

Board meetings FY2026

10 (100% attendance; Lin Yaomin 9/9)

Audit Committee

Wong (Chair), Lau, Lin; 2 meetings in FY2026

Remuneration Committee

Wong (Chair), Wu, Lau, Lin; 2 meetings

Nomination and CG Committee

Ng (Chair), Wong, Lau, Lin; 2 meetings

Retiring at 2026 AGM (9 Sep 2026)

Wu Qiyou, Lau Tak Kei Arthur (eligible for re-election)

Board & Management Changes

DateChangeSource

22 Aug 2023

Board reshuffle; Wu Qiyou appointed ED

AR26; Zonebourse

17 Apr 2024

Lin Yaomin appointed INED

AR25-RA

H1 FY2026

Dedicated hospital chief executive appointed for the Hainan project (name not disclosed)

IR26

H1 2026

Employee leading the Hainan licence application departed

AR26

Shareholding Trend

HolderShares at 31 Mar 2026% at 31 Mar 2026% after 28 Apr 2026 subscriptionSource

Solar Star Global Ltd (Ng family vehicle)

632,783,78456.13

46.78 (derived)

AR26

Ng Chi Lung (personal)

23,600,0002.09

1.74 (derived)

AR26

Ng Chi Lung and family (aggregate, incl. spouse Cheng Wai Yin)

656,383,78458.2248.52

AR26; PUBT 28 Apr 2026

New Hope International (HK) Ltd (ultimately Liu Yonghao)

68,643,5076.09

5.07 (derived)

AR26

—008.33

PUBT 28 Apr 2026

—008.33

PUBT 28 Apr 2026

Dejin Liangpin Co., Ltd (Wang Shaofeng)

300,000,000 (security interest)

26.61

22.18 (derived)

AR26

Competitive Landscape

Key Competitors

Competitor (ticker)Segment overlapRelative positioning vs. Good Fellow

Genertec Universal Medical (2666.HK)

Hospital groups

State-backed scale operator; Good Fellow is orders of magnitude smaller

China Resources Medical (1515.HK)

Hospital groups

SOE-backed hospital network; illustrates the PRC trend of closing loss-making private hospitals (it applied to close Huaiyin Hospital in 2024)

Hygeia Healthcare (6078.HK)

Specialty hospitals

Specialty oncology chain; the type of licensed-network model Good Fellow aspires to

New Century Healthcare (1518.HK)

Specialty (paediatric) hospitals, Beijing

Direct Beijing private-hospital comparator

Jinxin Fertility (1951.HK)

Specialty/consumer healthcare

Consumer-pay specialty model

Xikang Cloud Hospital (9686.HK)

Internet hospital / cloud hospital

H1 2026 revenue RMB182.9m, gross margin 23.5% (Xikang interim announcement, 26 Aug 2026), roughly 18x Good Fellow's half-year revenue

Ping An Healthcare and Technology (1833.HK)

Internet hospital / telemedicine

Platform scale, insurance-linked

JD Health (6618.HK)

Internet hospital / online pharmacy

Platform scale

Alibaba Health (0241.HK)

Internet hospital / online pharmacy

Platform scale

Boao Lecheng operators (36 operational institutions as of July 2025)

Hainan medical tourism

Established incumbents in the zone Good Fellow plans to enter

Peer Comparison FY2026

MetricGood Fellow (FY2026)Xikang Cloud Hospital (H1 2026)

Revenue

HK$20.06m (full year)

RMB182.9m (half year)

Gross margin

52.9%23.5%

Net result

Attributable loss HK$12.52m

Loss RMB27.4m (half year)

Recent Developments

--

Company Snapshot

$2.6M

Revenue

137

Employees

2001

Founded

Connaught Road Central, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Contractual revenue floor. The Yueerwan agreement guarantees at least HK$1.75m per month, about HK$21m per year, until October 2029, subject to the termination right [AR25-RA].
  • Repaired balance sheet. Equity moved from -HK$6.76m (FY2025) to net assets with gearing of only 5.75% (FY2026). Cash rose to HK$13.39m [AR25-RA; AR26].
  • Further capital raised. April 2026 added HK$19.09m of net proceeds, largely ring-fenced for healthcare investment [PUBT].
  • Hainan regulatory foothold. Establishment and site approvals for a Grade III specialty hospital in Boao Lecheng remain valid (dated 10 Dec 2025) [AR26].
  • Asset-light gross margin. Gross margin of 52.9% (FY2026) is above that of hospital and cloud-hospital peers such as Xikang (23.5%) (derived).
  • Independent board expertise. INEDs bring health insurance (Lin, former Kunlun Health Chairman) and investment banking/hedge fund experience (Lau, ex-Elliott) [AR26].

Weaknesses

  • Customer concentration. Effectively 100% of FY2026 revenue comes from one management contract (derived from AR26).
  • No operating hospital. The Beijing hospital has generated no revenue since December 2024 [AR26].
  • Losses widened despite growth. Attributable loss rose to HK$12.52m on 24% revenue growth. Operating margin was -61.7% (derived).
  • Disclosure quality. AR26 contains several errors and inconsistencies:
  • revenue growth stated as 22.44% vs 24.44%;
  • gross profit "decrease" when it increased;
  • capital-structure share count error;
  • about HK$6.6m of unitemised operating charges;
  • rights prospectus date inconsistencies;
  • a "no customer >5%" statement at odds with single-contract revenue.
  • Thin organisation. 28 employees and no CEO, against plans for Grade III hospital operation [AR26].
  • Regulatory compliance record. Beijing Zijing accumulated 13 demerit points in 2023, forcing a two-month suspension [HKEX-ANN 3 Jan 2024].

Opportunities

  • Licensed hospital acquisition. The Xiamen Huli Jianmin Hospital deal adds a 30-year licensed secondary hospital for RMB5.74m [PUBT 30 Jun 2026].
  • Yueerwan acquisition option. Could convert fee income into owned internet-hospital assets [AR25-RA].
  • Boao Lecheng growth. More than 20 additional institutions are in the pipeline and the zone has expedited approval pathways (Bernama, Jul 2025).
  • Distributable reserve. The capital reduction creates about HK$55.56m of distributable reserve, enabling future capital flexibility [AR26].
  • Specialty-care demand shift. Management-cited demand in cardiovascular, sports medicine and healthy ageing [AR26].
  • Performance kicker. The Yueerwan fee formula (1% of revenue plus 10% of PBT) provides upside if the internet hospital scales beyond the floor [AR25-RA].

Threats

  • Contract termination. Since October 2025 the counterparty can exit on three months' notice [AR25-RA].
  • Sector contraction. Hospital numbers fell 1% and beds 3% in 2025 (NHC via Yicai).
  • Regulatory change in Hainan. The approval process and competent authority changed, delaying the licence application [AR26].
  • Control and pledge risk. A 300m-share security interest (26.61%) in favour of Dejin Liangpin [AR26].
  • Dilution. Shares in issue rose from 563.6m (FY2025) to 1,352.8m (April 2026) through two equity raises [AR25-RA; PUBT].
  • Target quality. The Xiamen partnership lost RMB10.46m on RMB15.31m revenue in FY2026, and its reported net liabilities raise solvency questions [PUBT].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
14 Apr 2025Rights issue circular AR25-RAFund-raising to fix negative equity
17 Apr / 22 May 2025Rights issue prospectus (AR26 cites 17 Apr; AR25-RA cites 22 May; discrepancy noted) AR25-RA; AR26Documentation inconsistency
6 May 2025EGM; 2025 Share Option Scheme conditionally adopted AR26Incentive framework
13 May 20252025 Share Option Scheme becomes unconditional AR26—
16 May 2025Rights issue record date AR25-RA—
12 Jun 2025Rights issue results announcement AR25-RA—
26 Jun 2025FY2025 annual results; rights issue completed (net HK$26.794m) AR25-RA; AR26Return to positive equity
19 Sep 2025AGM held etnetRoutine
21 Nov 2025Profit warning: H1 loss approx. HK$2.7m against a prior-year profit Tiger/Stock NewsNo repeat of the disposal gain
28 Nov 2025Interim results: revenue HK$10.5m; Hainan leases signed; hospital chief executive appointed IR26Hainan strategy confirmed
10 Dec 2025Hainan Grade III specialty hospital establishment and site approvals AR26Key regulatory milestone
29 Dec 2025Interim Report 2025/26 published (focus on Hainan cardiovascular hospital) etnet—
10 Mar 2026Subscription of new shares under general mandate etnetFurther dilution
11 Mar 2026Clarification on use of subscription proceeds etnetDisclosure correction
12 Mar 2026Voluntary announcement of proposed share consolidation to meet GEM trading requirements etnetLow share price triggers corporate action
17 Apr 2026Capital reorganisation proposal (consolidation, capital reduction, sub-division of unissued shares) etnetRestructures par and creates reserves
28 Apr 2026Subscription completed: 225,459,995 shares at about HK$0.086; HK$19.39m gross, HK$19.09m net; family stake falls to 48.52% PUBTLoss of absolute majority; two 8.33% holders
11 May 2026Reorganisation circular and EGM notice PUBT; HKEX-ANN 26 Jun 2026—
3 Jun 2026EGM approves reorganisation AR26—
15 Jun 2026FY2026 annual results: revenue +24.4% to HK$20.06m; attributable loss HK$12.52m FY26-RALoss widens despite revenue growth
22–26 Jun 2026Reorganisation timetable set; first targeted effective date 24 Jun, then rescheduled to 15 Jul 2026 HKEX SMD/085/2026; HKEX-ANN 26 Jun 2026—
30 Jun 2026Agreement to acquire 80% of Chengkan (Xiamen) partnership for RMB5.74m PUBTFirst licensed-hospital acquisition
8 Jul 2026Clarification of parties and guarantors in the Xiamen deal PUBT/LongbridgeClerical correction
14 Jul 2026Reorganisation delayed: Cayman registration of solvency statement and EGM minute incomplete PUBTExecution slippage
23 Jul 2026Annual Report 2025/26 published; AGM notice issued PUBT—
9 Sep 2026AGM: re-election of Wu Qiyou and Lau Tak Kei Arthur; HLB reappointment; issue and repurchase mandates PUBTRoutine
22 Sep 2026Capital reorganisation effective; temporary counter 8567 HKEX-MKTShare count reduced fivefold
7 Oct 2026Parallel trading begins on 8143 (new) and 8567 (old) HKEX-MKTTechnical

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue fell from HKD 54.2 Mn in FY2022 to HKD 20.1 Mn in FY2026.
Good Fellow Healthcare Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue54.255.43916.120.1
Cost of sales——20.37.89.5
Gross profit——18.78.410.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Good Fellow Healthcare Holdings Limited, Annual Report 2025/2026 (hkexnews.hk)
  2. Annual Results Announcement FY2025 (www1.hkexnews.hk)
  3. FY2026 results summary (PUBT/Webull, 15 Jun 2026) (webull.hk)
  4. Annual Report publication summary (PUBT, 23 Jul 2026) (webull.hk)
  5. April 2026 subscription completion (PUBT) (webull.hk)
  6. Xiamen acquisition (PUBT, 30 Jun 2026) (webull.hk)
  7. Xiamen clarification (Longbridge, 8 Jul 2026) (longbridge.com)
  8. Reorganisation delay (PUBT, 14 Jul 2026) (webull.hk)
  9. EGM notice summary (PUBT, 11 May 2026) (webull.hk)
  10. AGM notice summary (PUBT, 23 Jul 2026) (webull.hk)
  11. HKEX share consolidation notice (effective 22 Sep 2026) (hkex.com.hk)
  12. HKEX parallel trading notice (7 Oct 2026) (hkex.com.hk)
  13. HKSCC circular on capital reorganisation (hkex.com.hk)
  14. HKEX SMD/146/2026 (hkex.com.hk)
  15. Reorganisation timetable announcement (26 Jun 2026) (www1.hkexnews.hk)
  16. Interim results H1 FY2026 (Bulletin Express via Tiger) (www-web.itiger.com)
  17. Interim profit warning (Nov 2025) (www-web.itiger.com)
  18. Beijing Zijing inside information (3 Jan 2024) (www1.hkexnews.hk)
  19. Beijing Zijing supplemental (31 Jan 2024) (www1.hkexnews.hk)
  20. FY2024 profit warning (www1.hkexnews.hk)
  21. 9M FY2023 profit warning (www1.hkexnews.hk)
  22. 2023 share consolidation (www1.hkexnews.hk)
  23. Edinburgh International Hospital licence (Jul 2020) (www1.hkexnews.hk)
  24. University of Edinburgh, "Edinburgh expertise helps found China hospital" (ed.ac.uk)
  25. Jiaxing hospital disposal (AAStocks via uSMART) (usmart.hk)
  26. etnet quote and company info (etnet.com.hk)
  27. etnet announcements list (etnet.com.hk)
  28. stoxray historical data (stoxray.com)
  29. TipRanks revenue history (tipranks.com)
  30. GuruFocus summary (test.gurufocus.com)
  31. Morningstar profile (morningstar.com.au)
  32. Xikang Cloud Hospital interim 2026 (hkexnews.hk)
  33. Yicai Global, China hospital numbers 2025 (yicaiglobal.com)
  34. NHC/China Daily on internet hospitals (2021) (en.nhc.gov.cn)
  35. Bernama on Boao Lecheng (Jul 2025) (bernama.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.